Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ELIZABETH A MAHER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1801847991
CMS profile
813082
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$74.94

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $74.94 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Novocure Inc. $74.94 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ELIZABETH A MAHER

NPI 1801847991 · CMS profile ID 813082

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801847991?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ELIZABETH A MAHER, NPI 1801847991, CMS profile ID 813082. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801847991?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ELIZABETH A MAHER, NPI 1801847991, CMS profile ID 813082. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801847991?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ELIZABETH A MAHER, NPI 1801847991, CMS profile ID 813082, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1801847991?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $74.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novocure Inc. $74.9406/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953392965 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $184.60 1
PY2021 $2,289.77 3
PY2022 $74.94 1
PY2023 $6,412.02 2
PY2024 $299.56 4
PY2025 $811.37 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $147,966.20 40
PY2024 Recipient $1,931.67 2
PY2024 Principal investigator $1,887,719.46 85
PY2023 Recipient $6,648.92 10
PY2023 Principal investigator $2,094,020.74 99
PY2021 Principal investigator $1,006,552.08 31
PY2020 Principal investigator $138,190.04 30
PY2019 Principal investigator $261,737.84 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Servier BioInnovation $32,188.60 12/18/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366319
Principal investigator 1 Servier BioInnovation $32,188.60 12/18/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366963
Principal investigator 1 Servier BioInnovation $32,188.60 12/18/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367123
Principal investigator 1 Servier BioInnovation $32,188.60 12/18/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367149
Recipient SERVIER AFFAIRES MEDICALES $445.73 12/07/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106877
Principal investigator 1 Servier BioInnovation $350.00 11/30/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367361
Principal investigator 1 Servier BioInnovation $350.00 11/30/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367377
Principal investigator 1 Servier BioInnovation $32,188.60 11/28/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366255
Principal investigator 1 Servier BioInnovation $32,188.60 11/28/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366387
Principal investigator 1 Servier BioInnovation $32,188.60 11/28/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366991
Principal investigator 1 Servier BioInnovation $32,188.60 11/28/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367007
Recipient SERVIER AFFAIRES MEDICALES $454.00 11/18/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106837
Recipient SERVIER AFFAIRES MEDICALES $469.66 11/18/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106885
Recipient SERVIER AFFAIRES MEDICALES $469.66 11/18/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106893
Principal investigator 1 Servier BioInnovation $1,477.00 10/31/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367415
Principal investigator 1 Servier BioInnovation $1,073.00 10/31/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367491
Principal investigator 1 Servier BioInnovation $643.80 10/31/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367517
Principal investigator 1 Servier BioInnovation $1,489.00 10/31/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367557
Principal investigator 1 Servier BioInnovation $1,073.00 10/31/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367651
Principal investigator 1 Servier BioInnovation $1,073.00 10/31/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367689
Principal investigator 1 Servier BioInnovation $32,188.60 10/16/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366337
Principal investigator 1 Servier BioInnovation $32,188.60 10/16/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366635
Principal investigator 1 Servier BioInnovation $32,188.60 10/16/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366669
Principal investigator 1 Servier BioInnovation $32,188.60 10/16/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366785
Recipient SERVIER AFFAIRES MEDICALES $198.29 10/10/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106829
Principal investigator 1 Servier BioInnovation $8,555.00 09/29/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367597
Principal investigator 1 Servier BioInnovation $965.70 09/29/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367625
Principal investigator 1 Servier BioInnovation $390.00 09/26/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1056367402
Principal investigator 1 Servier BioInnovation $32,188.60 09/21/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366405
Principal investigator 1 Servier BioInnovation $32,188.60 09/21/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366423
Principal investigator 1 Servier BioInnovation $32,188.60 09/21/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366823
Principal investigator 1 Servier BioInnovation $32,188.60 09/21/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367109
Principal investigator 1 Servier BioInnovation $390.00 09/08/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367465
Principal investigator 1 Servier BioInnovation $9,492.00 08/31/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367451
Recipient SERVIER AFFAIRES MEDICALES $1,659.35 08/17/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106853
Principal investigator 1 Servier BioInnovation $32,188.60 08/07/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366494
Principal investigator 1 Servier BioInnovation $32,188.60 08/07/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366553
Principal investigator 1 Servier BioInnovation $32,188.60 08/07/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366655
Principal investigator 1 Servier BioInnovation $32,188.60 08/07/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366885
Principal investigator 1 Servier BioInnovation $5,210.14 08/03/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1056367349
Principal investigator 1 Servier BioInnovation $32,188.60 07/24/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366455
Principal investigator 1 Servier BioInnovation $32,188.60 07/24/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366647
Principal investigator 1 Servier BioInnovation $32,188.60 07/24/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366681
Principal investigator 1 Servier BioInnovation $32,188.60 07/24/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367135
Principal investigator 1 Servier BioInnovation $32,188.60 06/19/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366271
Principal investigator 1 Servier BioInnovation $32,188.60 06/19/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366735
Principal investigator 1 Servier BioInnovation $32,188.60 06/19/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366911
Principal investigator 1 Servier BioInnovation $32,188.60 06/19/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366923
Principal investigator 1 Servier BioInnovation $195.00 06/14/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367529
Principal investigator 1 Servier BioInnovation $3,300.00 06/14/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367543
Principal investigator 1 Servier BioInnovation $12,200.00 06/14/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367663
Principal investigator 1 Servier BioInnovation $785.00 06/14/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367715
Recipient SERVIER AFFAIRES MEDICALES $308.33 06/09/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106845
Recipient SERVIER AFFAIRES MEDICALES $318.97 06/09/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106861
Recipient SERVIER AFFAIRES MEDICALES $318.97 06/09/2023 Covered Recipient Physician STUDY OF VORASIDENIB (AG-881) IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION (INDIGO) No dispute reported 06/30/2026 1055106869
Principal investigator 1 Servier BioInnovation $7,018.00 06/09/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367439
Principal investigator 1 Servier BioInnovation $1,931.40 05/31/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367583
Principal investigator 1 Servier BioInnovation $32,188.60 05/15/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366353
Principal investigator 1 Servier BioInnovation $32,188.60 05/15/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366437
Principal investigator 1 Servier BioInnovation $32,188.60 05/15/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366835
Principal investigator 1 Servier BioInnovation $32,188.60 05/15/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366861
Principal investigator 1 Servier BioInnovation $32,188.60 05/15/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366949
Principal investigator 1 Servier BioInnovation $32,188.60 05/15/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367094
Principal investigator 1 Servier BioInnovation $195.00 05/12/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1056367323
Principal investigator 1 Servier BioInnovation $1,500.00 05/12/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1056367335
Principal investigator 1 Servier BioInnovation $32,188.60 04/25/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366471
Principal investigator 1 Servier BioInnovation $32,188.60 04/25/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366579
Principal investigator 1 Servier BioInnovation $32,188.60 04/25/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366593
Principal investigator 1 Servier BioInnovation $32,188.60 04/25/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366607
Principal investigator 1 Servier BioInnovation $32,188.60 04/25/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366705
Principal investigator 1 Servier BioInnovation $32,188.60 04/25/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366813
Principal investigator 1 Servier BioInnovation $32,188.60 04/25/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367059
Principal investigator 1 Servier BioInnovation $32,188.60 04/25/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367175
Recipient SERVIER AFFAIRES MEDICALES $2,005.96 04/12/2023 Covered Recipient Physician STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS (CLARIDHY) (CLARIDHY) No dispute reported 06/30/2026 1055106821
Principal investigator 1 Servier BioInnovation $7,983.00 04/12/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367571
Principal investigator 1 Servier BioInnovation $325.00 03/16/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1056367297
Principal investigator 1 Servier BioInnovation $523.48 03/16/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1056367309
Principal investigator 1 Servier BioInnovation $1,540.50 03/16/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION No dispute reported 06/30/2026 1056367389
Principal investigator 1 Servier BioInnovation $2,897.10 03/13/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367609
Principal investigator 1 Servier BioInnovation $43.77 03/09/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 1056367187
Principal investigator 1 Servier BioInnovation $29.18 03/09/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 1056367199
Principal investigator 1 Servier BioInnovation $43.77 03/09/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation No dispute reported 06/30/2026 1056367213
Principal investigator 1 Servier BioInnovation $32,188.60 02/27/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366287
Principal investigator 1 Servier BioInnovation $32,188.60 02/27/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366529
Principal investigator 1 Servier BioInnovation $32,188.60 02/27/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366567
Principal investigator 1 Servier BioInnovation $32,188.60 02/27/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366775
Principal investigator 1 Servier BioInnovation $32,188.60 02/27/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366799
Principal investigator 1 Servier BioInnovation $32,188.60 02/27/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367021
Principal investigator 1 Servier BioInnovation $32,188.60 02/27/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367045
Principal investigator 1 Servier BioInnovation $32,188.60 02/27/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367085
Principal investigator 1 Servier BioInnovation $1,500.00 02/24/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367503
Principal investigator 1 Servier BioInnovation $14,216.00 02/24/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367703
Principal investigator 1 Servier BioInnovation $3,552.00 02/22/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367677
Principal investigator 1 Servier BioInnovation $965.70 02/13/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367477
Principal investigator 1 Servier BioInnovation $2,075.00 01/18/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367637
Principal investigator 1 Servier BioInnovation $1,477.00 01/18/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367729
Principal investigator 1 Servier BioInnovation $1,500.00 01/11/2023 Non-covered Recipient Entity
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO No dispute reported 06/30/2026 1056367425
Principal investigator 1 Servier BioInnovation $32,188.60 01/10/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366541
Principal investigator 1 Servier BioInnovation $32,188.60 01/10/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366693
Principal investigator 1 Servier BioInnovation $32,188.60 01/10/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366749
Principal investigator 1 Servier BioInnovation $32,188.60 01/10/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056367033
Principal investigator 1 Servier BioInnovation $32,188.60 01/03/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366303
Principal investigator 1 Servier BioInnovation $32,188.60 01/03/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366369
Principal investigator 1 Servier BioInnovation $32,188.60 01/03/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366511
Principal investigator 1 Servier BioInnovation $32,188.60 01/03/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366617
Principal investigator 1 Servier BioInnovation $32,188.60 01/03/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366723
Principal investigator 1 Servier BioInnovation $32,188.60 01/03/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366761
Principal investigator 1 Servier BioInnovation $32,188.60 01/03/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366937
Principal investigator 1 Servier BioInnovation $32,188.60 01/03/2023 Non-covered Recipient Entity
University of Texas Southwestern Medical Center
STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA No dispute reported 06/30/2026 1056366977